| GD |
Report |
Adjusted diluted EPS (Q2 2026) |
BEAT |
pred ~$4.03 vs. cons ~$3.96 |
MEDIUM |
| GD |
Report |
Total revenue (Q2 2026) |
BEAT |
pred ~$13.65B vs. cons ~$13.5B |
MEDIUM |
| GD |
Report |
Aerospace segment operating margin |
MISS |
pred ~14.6% vs. cons ~15.0% |
LOW |
| GD |
Guide |
FY2026 EPS guidance |
UNCHANGED |
guide ~$16.45-$16.55 vs. cons ~$16.50 (FY2026) |
MEDIUM |
| GD |
Guide |
FY2026 Free cash flow cadence/conversion |
UNCHANGED |
guide ~positive FCF each remaining quarter, ~$3.3-3.5B FY vs. cons ~$3.4B (FY2026) |
LOW |
| GD |
Guide |
Aerospace order/backlog commentary (Middle East demand) |
UNKNOWN |
guide ~qualitative stabilization vs. cons expecting continued softness (Q2 2026 / FY2026 outlook) |
LOW |
| GD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| GD |
Return |
5-day cumulative residual |
-2.3% (FADE) |
Stock has run +16% in two months into the print (24x trailing EPS, near all-time highs) on the back of a Q1 beat and mid-year guide raise, so a merely solid Q2 (flagged by management itself as a flattish, mix-heavy 'digestion' quarter) is unlikely to justify further multiple expansion; without a second consecutive guidance raise, sell-side will likely leave FY26 numbers roughly intact while trimming near-term Aerospace order assumptions given Middle East disruption, producing a 'beat-but-sell-the-news' day-1 dip that extends modestly over the week as investors rotate out of the crowded, highly-valued defense trade rather than add on an in-line-to-modest-beat result. |
MEDIUM |